Sarepta Therapeutics, Inc. (SRPT)
NASDAQ: SRPT · Real-Time Price · USD
61.76
+2.27 (3.82%)
Apr 24, 2025, 4:00 PM EDT - Market closed
Sarepta Therapeutics Stock Forecast
Stock Price Forecast
The 22 analysts with 12-month price forecasts for Sarepta Therapeutics stock have an average target of 153.5, with a low estimate of 75 and a high estimate of 230. The average target predicts an increase of 148.54% from the current stock price of 61.76.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Sarepta Therapeutics stock from 22 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 6 | 6 | 6 | 5 | 5 |
| Buy | 13 | 13 | 13 | 12 | 11 | 12 |
| Hold | 1 | 1 | 1 | 1 | 3 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 1 | 1 | 2 | 2 | 2 | 1 |
| Total | 22 | 21 | 22 | 21 | 21 | 22 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy Maintains $182 → $110 | Buy | Maintains | $182 → $110 | +78.11% | Apr 21, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates $75 | Hold | Reiterates | $75 | +21.44% | Apr 16, 2025 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $196 → $182 | Buy | Maintains | $196 → $182 | +194.69% | Apr 11, 2025 |
| Wells Fargo | Wells Fargo | Buy Initiates $115 | Buy | Initiates | $115 | +86.20% | Apr 11, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates $75 | Hold | Reiterates | $75 | +21.44% | Apr 7, 2025 |
Financial Forecast
Revenue This Year
3.17B
from 1.90B
Increased by 66.51%
Revenue Next Year
3.85B
from 3.17B
Increased by 21.66%
EPS This Year
7.17
from 2.34
Increased by 206.79%
EPS Next Year
12.68
from 7.17
Increased by 76.80%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 3.8B | 4.6B | 6.3B | ||
| Avg | 3.2B | 3.9B | 4.2B | ||
| Low | 2.6B | 2.9B | 2.9B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 100.7% | 46.0% | 63.6% | ||
| Avg | 66.5% | 21.7% | 8.5% | ||
| Low | 39.2% | -8.4% | -25.5% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 15.18 | 16.24 | 30.62 | ||
| Avg | 7.17 | 12.68 | 14.91 | ||
| Low | 1.09 | 7.64 | 5.03 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 549.3% | 126.4% | 141.4% | ||
| Avg | 206.8% | 76.8% | 17.6% | ||
| Low | -53.5% | 6.6% | -60.4% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.